DOD Chronic Pain Management, Clinical Exploration Award | W81XWH 21 CPMRP CEA

Opportunity Information: Apply for W81XWH 21 CPMRP CEA

The Department of Defense Chronic Pain Management, Clinical Exploration Award (FY21 CPMRP CEA; Funding Opportunity Number W81XWH 21 CPMRP CEA) is a research funding opportunity run through the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to push chronic pain care forward by funding early, clinically oriented studies that can quickly test promising ideas and remove real-world clinical barriers that currently limit effective pain management. The program emphasizes projects that are grounded in a clear, testable hypothesis and that can plausibly create a meaningful shift in how chronic pain is treated, rather than incremental work that only confirms what is already known.

At its core, the award supports proof-of-principle pilot studies, clinical trials, and correlative studies. In practical terms, that means applicants can propose smaller-scale studies that establish feasibility and early signals of benefit, more formal clinical trials that evaluate an intervention in people, and studies that connect clinical outcomes with biological, behavioral, or other measurable markers to help explain why an intervention works and for whom. The expectation is that these funded projects will produce strong scientific and clinical rationale for later, larger clinical trials, ultimately helping move the field toward interventions that can transform routine clinical care.

A defining feature of this opportunity is its focus on innovative, "outside-the-box" approaches. The DoD is looking for novel clinical concepts and creative avenues of investigation aimed at chronic pain management, especially where current practice falls short. Importantly, "novel" does not necessarily mean the therapy has never existed before; the program allows investigators to repurpose therapies that are already in clinical use or being tested for other conditions, as long as the proposed application to chronic pain would represent a major advancement in patient care. Applicants are expected to clearly explain what clinical knowledge gap their study addresses, why that gap matters for patients and providers, and how the results would set up the next steps toward changing clinical practice.

The opportunity also draws a clear boundary around opioid-related proposals. Projects that seek to develop new opioid-based therapeutic interventions are not aligned with the intent of this mechanism and may be withdrawn. However, studies that aim to understand, optimize, and reduce opioid utilization within the realities of current prescribing practices are considered acceptable. In other words, the program is open to research that helps clinicians and systems move toward safer, more effective chronic pain management with less reliance on opioids, but it is not meant to expand opioid therapeutic options.

From an administrative standpoint, the award is offered as either a grant or a cooperative agreement under the Science and Technology and other Research and Development category (CFDA 12.420). Eligibility is listed as unrestricted, meaning the competition is open to a broad range of applicant organizations, subject to any additional eligibility clarifications in the full announcement. The opportunity was posted June 15, 2021, with an original closing date of November 12, 2021, and it anticipated making about four awards. The listed award ceiling is shown as 0 in the source data, which typically indicates that the specific maximum budget may be defined elsewhere in the full funding announcement or handled through programmatic/budget negotiation rather than a single fixed cap.

Overall, this award mechanism is best understood as a launchpad for clinically relevant, hypothesis-driven innovation in chronic pain management: fund a well-justified early clinical study now, produce convincing evidence and mechanistic or correlative insight, and then use those results to support larger trials and, ultimately, changes in patient care.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Chronic Pain Management, Clinical Exploration Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 15, 2021.
• Applicants must submit their applications by Nov 12, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 CPMRP CEA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: